Single-level vertebral kyphoplasty is not associated with an increased risk of symptomatic secondary adjacent osteoporotic vertebral compression fractures: a matched case–control analysis

2018 ◽  
Vol 13 (1) ◽  
Author(s):  
Henrik Teuber ◽  
Simon Tiziani ◽  
Sascha Halvachizadeh ◽  
Diana Frey ◽  
Kai Sprengel ◽  
...  
Keyword(s):  
Case Control ◽  
Vertebral Compression Fractures ◽  
Control Analysis ◽  
Osteoporotic Vertebral Compression Fractures ◽  
Compression Fractures ◽  
Single Level ◽  
Increased Risk ◽  
Matched Case ◽  
Case Control Analysis

A Single Institution Retrospective Analysis of the Effect of Erythropoiesis Stimulating Agents in Patients with Multiple Myleoma

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 5701-5701
Author(s):  
Benjamin M Parsons ◽  
Andrew J Borgert ◽  
Angela Smith ◽  
Daniel Arndorfer
Keyword(s):  
Multiple Myeloma ◽  
Overall Survival ◽  
Logistic Regression ◽  
Case Control ◽  
Control Analysis ◽  
Product Labeling ◽  
Erythropoiesis Stimulating Agents ◽  
Increased Risk ◽  
Matched Case ◽  
Case Control Analysis

Abstract Background: Erythropoiesis Stimulating Agents (ESAs) are FDA approved for chemotherapy induced anemia and anemia of chronic kidney disease. These indications are more frequent in patients with multiple myeloma. Use of ESAs has been associated with an increased risk of heart attack, stroke, venous thromboembolism (VTE), and all-cause mortality. In patients with cancer, ESA's have been associated with worse progression free survival (PFS) and overall survival (OS) Previous research regarding ESA use in patients with multiple myeloma has been limited and conflicting. In this study, we evaluate the effects of ESA use in patients with multiple myeloma. Additionally, we examined the frequency of ESA usage after the 2007 FDA safety update revising product labeling for ESAs. Methods: A retrospective chart review was conducted on patients diagnosed with active multiple myeloma between January 1st, 2000 and December 31st, 2015 at Gundersen Health System in La Crosse Wisconsin. Collected data include patient demographics, medications, lab tests, comorbidities, and the dates of any VTE, stroke, or myocardial infarction. Both a logistic regression and a matched case-control analysis were used to compare rates of complications in patients using ESAs to those that did not. ESA effect on median survival time was also calculated for each International Staging System (ISS) stage of disease. Results:There were 278 patients included for demographic analysis (Table 1), of which 268 were included in the logistic regression analysis and 124 (62 pairs) in the matched case-control analysis. A logistic regression model constructed via stepwise selection found that bone lesions at diagnosis (Odds Ratio (OR): 2.5 [1.2-5.1]), antiplatelet drug use (OR: 3.7 [1.2-11.3]) and ESA use (OR: 4.7 [2.2-9.9]) were associated with increased risk of VTE in our patient population. Use of an Angiotensin Converting Enzyme (ACE) inhibitor (OR: 0.4 [0.2-0.9]) was associated with a decreased risk of VTE. Increased odds of VTE with ESA usage (OR: 5.9 [1.9 - 18.8]) were also noted in the matched case-control analysis. There was no association found between rate of stroke and ESA usage in either logistic or matched case-control analysis. No significant association between ESA use and overall survival was noted in either logistic or matched case-control analysis. When comparing outcomes based upon pre and post FDA revised product labeling, we found a 50% reduction in ESA usage within our institution. In this same time period, the percentage of patients with multiple myeloma developing VTEs has been significantly reduced (18.6% vs 12.8% [p<0.007]). Conclusions: In our population, the use of ESAs in multiple myeloma patients was associated with increased risk of VTE. No significant association between ESA use and overall survival was noted. The observed decrease in both ESA use and rate of VTE in patients with myeloma after the 2007 revised safety labelling by the FDA may reflect practice changes in response to this revision at our institution. Further study in a prospective large multicenter dataset with further control of confounding variables is warranted. Table 1 Table 1. Disclosures No relevant conflicts of interest to declare.

Influence of Prognostic Risk Indicators on Osseointegrated Dental Implant Failure: A Matched Case-Control Analysis

2012 ◽  
Vol 38 (1) ◽  
pp. 51-61 ◽  
Author(s):  
Rami Alissa ◽  
Richard J. Oliver
Keyword(s):  
Dental Implant ◽  
Case Control ◽  
Implant Failure ◽  
Risk Indicators ◽  
Therapeutic Modality ◽  
Control Analysis ◽  
Wide Diameter ◽  
Related Risk ◽  
Matched Case ◽  
Case Control Analysis

Dental implant treatment is an important therapeutic modality with documented long-term success for replacement of missing teeth. However, dental implants can be susceptible to disease conditions or healing complications that may lead to implant loss. This case-control study identified several risk indicators associated with failure such as smoking and alcohol consumption. The use of postoperative antibiotics or wide-diameter implants may significantly reduce implant failure. Knowledge of patient-related risk factors may assist the clinician in proper case selection and treatment planning.

scholarly journals Life-threatening alcohol-related traffic crashes in adverse weather: a double-matched case–control analysis from Canada

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e024415 ◽  
Author(s):  
Donald A Redelmeier ◽  
Fizza Manzoor
Keyword(s):  
Relative Risk ◽  
Case Control ◽  
Additional Patient ◽  
Control Analysis ◽  
Drinking And Driving ◽  
Traffic Crash ◽  
Adverse Weather ◽  
Life Threatening ◽  
Matched Case ◽  
Case Control Analysis

ImportanceDrunk driving is a major cause of death in North America, yet physicians rarely counsel patients on the risks of drinking and driving.ObjectiveTo test whether the risks of a life-threatening alcohol-related traffic crash were further accentuated by adverse weather.DesignDouble matched case–control analysis of hospitalised patients.SettingCanada’s largest trauma centre between 1 January 1995 and 1 January 2015.ParticipantsPatients hospitalised due to a life-threatening alcohol-related traffic crash.ExposureRelative risk of a crash associated with adverse weather estimated by evaluating the weather at the place and time of the crash (cases) compared with the weather at the same place and time a week earlier and a week later (controls).ResultsA total of 2088 patients were included, of whom the majority were drivers injured at night. Adverse weather prevailed among 312 alcohol-related crashes and was significantly more frequent compared with control circumstances. The relative risk of a life-threatening alcohol-related traffic crash was 19% higher during adverse weather compared with normal weather (95% CI: 5 to 35, p=0.006). The absolute increase in risk amounted to 43 additional crashes, extended to diverse groups of patients, applied during night-time and daytime, contributed to about 793 additional patient-days in hospital and was distinct from the risks for drivers who were negative for alcohol.ConclusionsAdverse weather was associated with an increased risk of a life-threatening alcohol-related traffic crash. An awareness of this risk might inform warnings to patients about traffic safety and counselling alternatives to drinking and driving.

Morbidity of Staged Proctectomy After Hepatectomy for Colorectal Cancer: A Matched Case–Control Analysis

2012 ◽  
Vol 20 (2) ◽  
pp. 482-490 ◽  
Author(s):  
Ching-Wei D. Tzeng ◽  
Thomas A. Aloia ◽  
Jean-Nicolas Vauthey ◽  
George J. Chang ◽  
Lee M. Ellis ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Case Control ◽  
Control Analysis ◽  
Matched Case ◽  
Case Control Analysis

Does Partial Cystectomy Compromise Oncologic Outcomes for Patients with Bladder Cancer Compared to Radical Cystectomy? A Matched Case-Control Analysis

2012 ◽  
Vol 188 (4) ◽  
pp. 1115-1119 ◽  
Author(s):  
John J. Knoedler ◽  
Stephen A. Boorjian ◽  
Simon P. Kim ◽  
Christopher J. Weight ◽  
Prabin Thapa ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Radical Cystectomy ◽  
Case Control ◽  
Partial Cystectomy ◽  
Oncologic Outcomes ◽  
Control Analysis ◽  
Matched Case ◽  
Case Control Analysis

Postmastectomy Radiation and Mortality in Women With T1-2 Node-Positive Breast Cancer

2005 ◽  
Vol 23 (7) ◽  
pp. 1409-1419 ◽  
Author(s):  
Benjamin D. Smith ◽  
Grace L. Smith ◽  
Bruce G. Haffty
Keyword(s):  
Breast Cancer ◽  
Case Control ◽  
Control Analysis ◽  
Regional Lymph Nodes ◽  
Node Positive ◽  
Specific Mortality ◽  
Matched Case ◽  
Case Control Analysis ◽  
The Relationship ◽  
Positive Breast Cancer

Purpose To determine the relationship between postmastectomy radiotherapy (PMRT) and mortality in a population-based cohort of women with T1-2 node-positive breast cancer. Patients and Methods Using data from the Surveillance, Epidemiology, and End Results program, we identified 18,038 women with T1-2 node-positive invasive breast cancer who were treated with mastectomy between 1988 and 1995. The relationship between PMRT and mortality was determined using proportional hazards multivariate modeling and propensity score matched case-control analysis. Results Median follow-up was 8.1 years. Only 2,648 women (15%) received PMRT. After adjusting for covariates, PMRT use was not associated with mortality (hazard ratio [HR] = 0.96; 95% CI, 0.90 to 1.03). However, the interaction term for PMRT use and number of involved regional lymph nodes was significant (P = .002), suggesting that, above a certain threshold of involved nodes, a mortality benefit from PMRT may exist. Adjusted analysis stratified by number of involved nodes revealed that patients with seven or more involved nodes treated with PMRT experienced a significant reduction in all-cause (HR = 0.84; 95% CI, 0.76 to 0.93) and cause-specific mortality (HR = 0.86; 95% CI, 0.77 to 0.96). Propensity score matched case-control analysis confirmed that PMRT was associated with reduced mortality only in the subset of patients with seven or more involved nodes (HR = 0.81; 95% CI, 0.73 to 0.91 for all-cause mortality; and HR = 0.82; 95% CI, 0.72 to 0.93 for cause-specific mortality). Conclusion For women with T1-2 breast cancer, PMRT is associated with a 15% to 20% relative reduction in mortality for patients with seven or more involved regional lymph nodes.

Sign in / Sign up

Export Citation Format

Share Document